Indaptus Therapeutics, Inc.
37.10%
41,991,000
1857044
Apr 27, 2026
Apr 29, 2026, 04:05 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Yao Yun | Individual | 37.10% | 41,991,000 | 41,991,000 | 0 |
| SINO LION VENTURES Ltd | Partnership | 34.30% | 38,895,000 | 0 | 38,895,000 |
| Xu Chenhao | Individual | 34.30% | 38,895,000 | 0 | 38,895,000 |
| Dai Junyi | Individual | 9.90% | 11,250,000 | 11,250,000 | 0 |
| Yang Ting | Individual | 9.90% | 11,250,000 | 11,250,000 | 0 |
| Deng Lina | Individual | 4.90% | 5,550,000 | 5,550,000 | 0 |
Disclosure Items (4)
Common Stock, $0.01 par value
Indaptus Therapeutics, Inc.
c/o Indaptus Therapeutics, Inc., New York, NY, 10019
Item 2(a) of the Original Schedule 13D is amended by adding the following sentence: For the purpose of clarification, the Reporting Persons have disbanded their group to the extent they may have been deemed to be a group and will no longer operate as a group.
The information contained in rows 11 and 13 of the cover pages of this Schedule 13D (including the accompanying comments thereto) is incorporated herein by reference. The ownership information presented herein represents beneficial ownership of shares of Common Stock as of the date of this filing, based upon 113,242,324 shares of Common Stock outstanding as of March 31, 2026.
The information contained in rows 7 through 10 of the cover pages of this Amendment (including the accompanying comments thereto) is incorporated herein by reference.
Except as described in this Amendment, none of the Reporting Persons have effected any transaction in the shares of Common Stock during the past 60 days.
No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities.
As a result of an increase in the number of shares of Common Stock outstanding of the Issuer, Lina Deng ceased to be the beneficial owner of more than five percent of the shares of the Issuer's Common Stock.
Exhibit 1: Joint Filing Agreement, dated as of March 30, 2026, by and among Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang, and Lina Deng (incorporated by reference to Exhibit 99.2 to the Schedule 13D filed with the SEC by the Reporting Persons on March 30, 2026). https://www.sec.gov/Archives/edgar/data/1857044/000182912626002858/indaptustherap_ex99-2.htm